Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zomedica Pharma approved for listing by NYSE American

Stockhouse Editorial
0 Comments| November 10, 2017

{{labelSign}}  Favorites
{{errorMessage}}

Zomedica Pharmaceuticals Corp. (TSX: V.ZOM, ZOMHF, Forum), said its shares have been approved for listing by NYSE American. Trading of the common shares on the NYSE American will not commence until after Zomedica’s Registration Statement on Form S-1 is declared effective by the U.S. Securities and Exchange Commission.

With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical and health care solutions company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica is developing a diversified portfolio to include diagnostics, devices, innovative drugs, and drug-delivery technologies.

More information can be found here.

Zomedica was in the news recently when the company announced its financial results for the three and nine months ended September 30, 2017.

Full Disclosure: Zomedica Pharmaceuticals Corp. is a paid client of Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today